Cargando…
Cost of persistent asthma in Italy
BACKGROUND: Asthma is a common disease of the airways with a significant burden for the society and for patients’ quality of life. The Social Impact of Respiratory Integrated Outcomes (SIRIO) study estimated a mean cost of 1,177.40 € per patient/year in Italy, in 2007. The aim of the present study w...
Autores principales: | Dal Negro, Roberto W., Distante, Chiara, Bonadiman, Luca, Turco, Paola, Iannazzo, Sergio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5162079/ https://www.ncbi.nlm.nih.gov/pubmed/28018593 http://dx.doi.org/10.1186/s40248-016-0080-1 |
Ejemplares similares
-
Fluticasone furoate/Vilanterol 92/22 μg once-a-day vs Beclomethasone dipropionate/ Formoterol 100/6 μg b.i.d.: a 12-week cost analysis in mild-to-moderate asthma
por: Dal Negro, Roberto W., et al.
Publicado: (2016) -
Costs of illness analysis in Italian patients with chronic obstructive pulmonary disease (COPD): an update
por: Dal Negro, Roberto W, et al.
Publicado: (2015) -
Fluticasone furoate/vilanterol 92/22 µg once a day: a 12-month study on outcomes in mild to moderate asthma
por: Dal Negro, Roberto W., et al.
Publicado: (2018) -
Fluticasone furoate/Vilanterol 92/22 μg once-a-day vs Beclomethasone dipropionate/Formoterol 100/6 μg b.I.D.: a 12-month comparison of outcomes in mild-to-moderate asthma
por: Dal Negro, Roberto W., et al.
Publicado: (2018) -
Correction to: Fluticasone furoate/Vilanterol 92/22 μg once-a-day vs Beclomethasone dipropionate/Formoterol 100/6 μg b.I.D.: a 12-month comparison of outcomes in mild-to-moderate asthma
por: Dal Negro, Roberto W., et al.
Publicado: (2018)